LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients



Status:Completed
Conditions:Hepatitis, Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:7/15/2018
Start Date:June 1, 2016
End Date:June 30, 2018

Use our guide to learn which trials are right for you!

The predominant remaining questions for post-transplant treatment of HCV in the DAA era are
whether a ribavirin-free regimen is possible and whether pre-emptive treatment is now a
potential option to prevent long-term damage to the allograft.

Our aim is to provide answers to these primary questions with our multicenter, prospective,
randomized, open-label intent-to-treat phase IV study

This is a multicenter, prospective, randomized, open-label phase IV study.

Compare ledipasvir/sofosbuvir + ribavirin for 12 weeks vs ledipasvir/sofosbuvir alone for 12
weeks in patients over 90 days post-liver transplant

Inclusion Criteria

1. At least 18 years of age and able to give informed consent

2. History of HCV genotype 1 or 4

3. Normal EKG

4. At least 91 days post orthotopic liver transplant

5. Screening laboratory values within defined thresholds

6. Detectable HCV RNA at screening

7. Creatinine Clearance of at least 40ml/min using the Cockroft Gault equa-tion

8. Negative pregnancy test for female subjects within 48 hours prior to re-ceiving study
medication

9. Use of two effective contraception methods if female of childbearing po-tential or
sexually active male unless status post bilateral tubal ligatation, bilateral
oophorectomy, hysterectomy, or vasectomy

Exclusion Criteria

1. Serious or active medical or psychiatric illness

2. History of significant or unstable cardiac disease

3. Stomach disorder that could interfere with the absorption of the study drug

4. Pregnant or nursing females or males with a pregnant female partner

5. Co-infected with HBV or HIV

6. Recipients of an allograft from a donor that was infected with HCV with an unknown
genotype or non-genotype 1 or 4 unless the recipient is demonstrated to have only
genotype 1 or 4 HCV replication post-transplant

7. Allergic to or intolerant of sofosbuvir, ledipasvir, or ribavirin

8. History of exposure to an NS5A inhibitor

9. Within 1 year of transplant AND history of Hepatocellular Carcinoma (HCC) with tumor
burden outside of the Milan Criteria (See Appendix II) prior to transplant

10. Participated in a clinical study with an investigational drug or biologic within the
last 30 days

11. Combined liver/kidney transplant

12. History of organ transplant other than liver

13. Childs Turcotte Pugh (CTP) B or C

14. Patients with fibrosing cholestatic hepatitis

15. Platelet count of ≤ 30 k/mm3

16. Hemoglobin < 10g/dL

17. Total bilirubin > 10mg/dL

18. ALT, AST, or alkaline phosphatase ≥ 10x ULN

19. Serum sodium < 125mmol/L

20. Current use of any of the Prohibited Interventions (Section 5.3.2) and un-willing to
discontinue use, or use of amiodarone within 6 months of screening
We found this trial at
4
sites
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Kenneth Chavin, MD
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Principal Investigator: Naudia Jonassaint, MD
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Washington, District of Columbia 20007
Principal Investigator: Rohit Satoskar, MD
?
mi
from
Washington,
Click here to add this to my saved trials